This study is intended to find out which dose of Atracurium produces better quality of muscle relaxation - 0.75 mg/kg or 1 mg/ kg
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2024/01/061812
- Lead Sponsor
- Department of Anaesthesiology, Sawai Man Singh Medical College and Attached Hospitals
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients undergoing surgery under general anaesthesia, with BMI 18.5 to 24.9 and ASA grades 1 and 2
Exclusion Criteria
Patients with cardiovascular comorbidities, jaundice, bronchial asthma, epilepsy, uncontrolled diabetes mellitus or hypertension, metabolic or endocrine disease, morbid obesity or any chronic illness or allergy to study drug.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of Atracurium's neuromuscular blockade in general anesthesia?
How does the 0.75 mg/kg vs. 1 mg/kg Atracurium compare to standard neuromuscular blockers in efficacy and safety?
What are the primary clinical endpoints of the CTRI/2024/01/061812 Atracurium dose comparison trial?
Which biomarkers predict optimal muscle relaxation response to Atracurium dosing in surgical patients?
What are the known adverse events associated with Atracurium dosing in general anesthesia and their management strategies?